Many times IPOs get subscribed because there is a grey market premium going on. Now why should we allow this grey market premium to influence IPO? If you really want a grey market premium to influence investors, then why not create a when-issued market?
AstraZeneca Pharma shares rally 13%, hit 52-week high after receiving nod for cancer drug Durvalumab
AstraZeneca Pharma Share Price: The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages (SMAs).